3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Blood Specimen Collection
5
Drug Therapy
3
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Carboplatin
2
Biopsy, Large-Core Needle
2
Biopsy
2
toripalimab
1
tislelizumab
1
taxane
1
sacituzumab govitecan
1
pembrolizumab
1
atezolizumab
1
Zoledronic Acid
1
Urine Specimen Collection
1
Prophylactic Mastectomy
1
Paracentesis
1
Neuropsychological Tests
1
Mifepristone
1
Medicine, Chinese Traditional
1
Mastectomy, Segmental
1
Magnetic Resonance Spectroscopy
1
Interviews as Topic
1
Immunotherapy
1
Immunohistochemistry
1
Gene Expression Profiling
1
Doxorubicin
1
DNA
1
Cyclophosphamide
1
Combined Modality Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Triple Negative Breast Neoplasms
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled